NCT04474379Active, not recruiting
Everyday Memory Impairment in PD-related Cognitive Decline
Prospective Memory Impairment in Parkinson Disease-related Cognitive Decline: Intervention and Mechanisms
Source: ClinicalTrials.gov · Last updated 18 Mar 2026
Brief summary (registry, in English)
The investigators will aim enroll participants into our study within 3-6 months after their parent study visit so the investigators can utilize some key data points (e.g. PD-MCI diagnosis, rs-fcMRI data) from that study. PD participants will participate in a single-blind RCT with two treatment arms: process training and strategy training (Fig 4). They will complete pre-training assessment (Pre), be randomized to treatment arm (1:1 ratio stratified by sex), and then complete 8 training sessions over an 8-week period. They will return within 1 week for post-training assessment (Post) and then will complete Follow-up (FU) assessments via web or mailed survey 3 and 6 months after training ends. They will complete a 12mo FU assessment in person in conjunction with their annual parent study visit. HC participants will complete prospective memory assessment at one time point coinciding with (or within 3-6 months of) their parent study visit to determine whether any relationships observed between rs-fcMRI data and prospective memory are specific to PD.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 10 Jul 2020
- Start date
- 29 Nov 2021
- Primary completion date
- 12 Mar 2026
- Lead sponsor
- Washington University School of Medicine
- Diseases
- Parkinson disease
- NCT number
- NCT04474379
What you commit to
- Study type: Interventional
- Planned participants: 120
- From 29 Nov 2021 to the primary completion date, 12 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with medications that interfere with cognition (e.g. anticholinergics).
Other illness
- Dementia according to MDS criteria or MoCA score \<21.
- Other neurological disorders (e.g. stroke, seizures), brain surgery, severe systemic diseases, major psychiatric disorder or history of psychotic symptoms (e.g. schizophrenia, bipolar disorder, delusions, hallucinations), or drug abuse.
- Any other condition that would interfere with participation (e.g., non-English speaking, significant current depression).
- Psychiatric conditions/ symptoms that are common in PD (e.g. anxiety, depression) are allowed if they are deemed insufficient to interfere with participation.
Who the study is looking for
- Males and females over age 50 who meet criteria for typical idiopathic PD
- Hoehn \& Yahr stage I-III,
- Treated with levodopa/carbidopa
- Have subjective memory complaints (as identified in phone screen),
- Have an informant to complete relevant ratings,
- Medications should be stable for 4 weeks prior with no changes planned during the treatment portion of the study (Pre to Post); changes over the follow-up period will be tracked and accounted for as appropriate.
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Washington University School of Medicine Coordinator of this site? Confirm its status | St Louis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.